Hematologic Oncology | Specialty

CPX-351 Delivers Durable Improvement in OS in Older Patients With AML in Longer Follow-up

June 30th 2021

The fixed combination of daunorubicin and cytarabine continued to demonstrate improved overall survival vs 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Using NGS to Inform More Than Diagnosis in Myeloid Malignancies

June 29th 2021

Next-generation sequencing plays a critical role in the diagnosis of patients with myeloid malignancies, but it also plays a necessary role in the identification of passenger mutations and subclonal events that go beyond founding drivers.

Therapeutic Decision-Making for Primary Myelofibrosis

June 29th 2021

Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.

Diagnosis and Prognosis of Primary Myelofibrosis

June 29th 2021

A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.

Phase 1 CYNK-001 Trial Expands to Include Relapsed/Refractory AML Population

June 29th 2021

A phase 1 study evaluating the off-the-shelf cell therapy CYNK-001 has expanded to include patients with relapsed/refractory acute myeloid leukemia after a case of conversion to minimal residual disease negativity at its highest dose level.

Lee-Kim on Fostering a Fulfilling Fellowship in Oncology

June 28th 2021

Dr. Lee-Kim discusses her path into treating pediatric patients with cancer, key lessons that can be learned during fellowship, and tips on managing finances and burnout during a pediatric oncology fellowship program.

Atallah Breaks Down Key Advances Made Across Leukemias and Lymphomas

June 27th 2021

Ehab Atallah, MD, spotlights recent updates, emerging approaches, and next steps for research in leukemia and lymphoma.

Loncastuximab Tesirine Continues to Impress in Relapsed/Refractory DLBCL and MCL

June 23rd 2021

Loncastuximab tesirine-lpyl continued to demonstrate promising antitumor activity with an acceptable toxicity profile when used in the treatment of select patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma.

Subcutaneous Daratumumab Approved in Europe for Newly Diagnosed Light-Chain Amyloidosis, Pretreated Myeloma

June 22nd 2021

The European Commission has granted marketing authorization for the expanded use of subcutaneous daratumumab for use in 2 new indications.

Camidanlumab Tesirine Elicits Encouraging ORR in Heavily Pretreated Hodgkin Lymphoma

June 22nd 2021

Camidanlumab tesirine was found to elicit an objective response rate of 66.3% in patients with relapsed/refractory Hodgkin lymphoma.

Dr. Michaelis on Safety Considerations With Venetoclax/Azacitidine in AML

June 21st 2021

Laura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.

Navigating Newfound Options, MRD Assessment, and Emerging Approaches in Multiple Myeloma

June 21st 2021

The expanding therapeutic landscape in multiple myeloma is poised to integrate daratumumab-based quadruplet therapies and novel cellular therapies as standard options for patients with newly diagnosed and relapsed/refractory disease.

Zanubrutinib Approved in China for Relapsed/Refractory Waldenström Macroglobulinemia

June 21st 2021

The China National Medical Products Administration has granted a conditional approval to zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia who have previously received at least 1 therapy.

FDA, EU Approval Sought for Copanlisib Plus Rituximab for Indolent Non-Hodgkin Lymphoma

June 21st 2021

A supplemental new drug application and a marketing authorization application seeking the approval of the combination of copanlisib and rituximab for the treatment of patients with indolent non-Hodgkin lymphoma have been submitted to the FDA and the European Medicines Agency, respectively.

Oral Azacitidine Approved in Europe for Frontline Maintenance in AML

June 18th 2021

The European Commission has granted full marketing authorization to azacitidine tablets for use as a maintenance therapy in adult patients with acute myeloid leukemia who achieved complete remission or CR with incomplete blood recovery after induction therapy with or without consolidation treatment, and who are not eligible for, or do not choose to proceed to, hematopoietic stem cell transplant.

Moving Curative Therapies Forward in Hematologic Malignancies

June 17th 2021

Because hematological cancers are rarer than solid tumors, information on treatment practices is somewhat less available, so hematologists are particularly interested in learning what their peers are doing.

Frontline Eprenetapopt Plus Venetoclax/Azacitidine Elicits CR Rate of 37% in TP53-Mutated AML

June 16th 2021

The 3-drug combination comprised of eprenetapopt, venetoclax, and azacitidine was found to induce a complete remission rate of 37% in patients with TP53-mutant acute myeloid leukemia.

Oncology Leaves Its Mark on 2020 Research and Development Trends

June 16th 2021

Rates of clinical trial initiation, novel drug development, and collaborative research and development deals were oncology.

Iomab-B Continues to Showcase Impressive Bone Marrow Transplant and Engraftment Rate in Relapsed/Refractory AML

June 15th 2021

Iodoine apamistamab, a radiotherapy that targets CD45-expressing cells, demonstrated a 100% bone marrow transplant and engraftment rate in patients with relapsed/refractory acute myeloid leukemia vs 18% for those who received a physician’s choice of salvage treatment.

Brexucabtagene Autoleucel Safe, Efficacious as Therapy for Pediatric B-Cell ALL in ZUMA-4

June 13th 2021